The concurrent use of PD-1/PD-L1 inhibitors (e.g., nivolumab, pembrolizumab) and CTLA-4 inhibitors (e.g., ipilimumab) has demonstrated promising clinical outcomes across various tumor types. The gene discussed is CTLA4; the disease is neoplasm.